T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1451
Box
BOX
$4.48B
| $4.13M | ﹤0.01% |
137,887
-830,976
| -86% | -$26.1M |
|
1452
Indivior Pharmaceuticals
INDV
$4.57B
| $4.12M | ﹤0.01% |
114,907
+28,746
| +33% | +$878K |
|
1453
Universal Display
OLED
$4.18B
| $4.11M | ﹤0.01% |
35,157
+2,284
| +7% | +$296K |
|
1454
Archrock
AROC
$5.84B
| $4.11M | ﹤0.01% |
157,760
-391,530
| -71% | -$9.74M |
|
1455
Bank OZK
OZK
$5.69B
| $4.1M | ﹤0.01% |
89,064
+4,114
| +5% | +$192K |
|
1456
Klaviyo
KVYO
$5.47B
| $4.1M | ﹤0.01% |
126,104
+9,393
| +8% | +$263K |
|
1457
iShares National Muni Bond ETF
MUB
$45.9B
| – | – |
0
| – | – |
|
1458
Post Holdings
POST
$3.65B
| $4.09M | ﹤0.01% |
41,293
-537,740
| -93% | -$55.7M |
|
1459
NewAmsterdam Pharma
NAMS
$3.19B
| $4.08M | ﹤0.01% |
116,258
-22,071
| -16% | -$803K |
|
1460
Sunrun
RUN
$2.37B
| $4.07M | ﹤0.01% |
221,283
+1,732
| +0.8% | +$33.2K |
|
1461
iShares Russell 2000 Growth ETF
IWO
$15.1B
| $4.07M | ﹤0.01% |
12,586
+2,630
| +26% | +$855K |
|
1462
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$5.44B
| $4.06M | ﹤0.01% |
129,029
+9,063
| +8% | +$285K |
|
1463
NewtekOne
NEWT
$370M
| $4.05M | ﹤0.01% |
357,106
+340,000
| +1,988% | +$3.71M |
|
1464
Vail Resorts
MTN
$5.29B
| $4.04M | ﹤0.01% |
30,422
+1,124
| +4% | +$165K |
|
|
FOLD
1465
DELISTED
Amicus Therapeutics
FOLD
| $4.01M | ﹤0.01% |
281,842
-774,019
| -73% | -$7.6M |
|
|
CBIO
1466
Crescent Biopharma
CBIO
$610M
| $4.01M | ﹤0.01% |
338,125
-45,470
| -12% | -$579K |
|
1467
Dropbox
DBX
$7.31B
| $3.99M | ﹤0.01% |
143,314
+8,311
| +6% | +$242K |
|
1468
Caesars Entertainment
CZR
$6.04B
| $3.96M | ﹤0.01% |
169,153
+7,845
| +5% | +$176K |
|
1469
Saic
SAIC
$5.35B
| $3.94M | ﹤0.01% |
39,124
+1,569
| +4% | +$150K |
|
1470
First Financial Bankshares
FFIN
$5.01B
| $3.93M | ﹤0.01% |
131,462
+10,128
| +8% | +$319K |
|
1471
Texas Capital Bancshares
TCBI
$4.38B
| $3.93M | ﹤0.01% |
43,371
+1,240
| +3% | +$109K |
|
1472
CNO Financial Group
CNO
$5.02B
| $3.92M | ﹤0.01% |
92,413
+2,612
| +3% | +$106K |
|
1473
Phillips Edison & Co
PECO
$5.2B
| $3.86M | ﹤0.01% |
108,618
+3,519
| +3% | +$122K |
|
1474
Silicon Laboratories
SLAB
$7.3B
| $3.84M | ﹤0.01% |
29,393
+1,744
| +6% | +$229K |
|
1475
Associated Banc-Corp
ASB
$6.07B
| $3.84M | ﹤0.01% |
148,927
+4,628
| +3% | +$119K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.